Antiemetic Efficacy of Granisetron: a Randomized Crossover Study in Patients Receiving Cisplatin-containing Intraarterial Chemotherapy
| Autor: | Hideyuki Akaza, Satoru Ishikawa, Shiro Hinotsu, Kenkichi Koiso, Kazunori Hattori, Mikinobu Ohtani, Fukuji Kondo, Noguchi R, Katsunori Uchida |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
Cancer Research Antiemetic Agent Adolescent medicine.drug_class Nausea medicine.medical_treatment Antineoplastic Agents Granisetron Drug Administration Schedule medicine Humans Infusions Intra-Arterial Antiemetic Radiology Nuclear Medicine and imaging Prospective Studies Aged Aged 80 and over Chemotherapy Cross-Over Studies business.industry General Medicine Middle Aged Chemotherapy regimen Crossover study Methotrexate Urinary Bladder Neoplasms Oncology Anesthesia Vomiting Antiemetics Female Vomiting Anticipatory Cisplatin medicine.symptom business medicine.drug |
| Zdroj: | Japanese Journal of Clinical Oncology. 29:87-91 |
| ISSN: | 1465-3621 0368-2811 |
| Popis: | Cisplatin (CDDP) is one of the most active chemotherapeutic agents but is among the most emetogenic drugs. The emetic side-effects of CDDP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of CDDP administration has not been assessed.CDDP 50 mg/m2 and methotrexate 30 mg/m2 were administered every 3 weeks through intraarterial catheters placed in the bilateral internal iliac arteries. Patients were classified into two groups: granisetron treatment group (group G) and no treatment group (group NG) with the first course of chemotherapy, crossing over with the second course. The patients in group G received granisetron 40 micrograms/kg by intravenous infusion.Although intraarterial CDDP administration produced less emesis than intravenous CDDP administration, at the same concentration, gastrointestinal toxicity is still the most unpleasant side-effect for patients. Granisetron administration significantly reduced nausea and vomiting during the acute emetic phase (an evaluation of treatment as very effective and effective was made in 89% in group G and 33% in group NG (P0.001). Complete control of emesis was achieved in 68 and 18% of patients in groups G and NG, respectively (P0.0001).A single prophylactic infusion of granisetron was effective in preventing the nausea and vomiting associated with intraarterial CDDP-containing therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|